13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001502287
Total reported value
$2.2B
$2.2B
16 檔
3.9%
As reported in its official Q1 2025 Form 13F filing, StepStone Group LP's tracked investment portfolio stood at $2.2B with 16 total positions.
In Q1 2025, StepStone Group LP displayed an active expansion posture, initiating 16 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including MONEYLION INC, PATH, DKNG) accounted for 3.9% of total reported equity market value during Q1 2025.
Top New Position Initiated
MONEYLION INC
市值: $52.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Moneylion Inc | Stock-Other | 54.09% | — | — | |
| 2 | PATH | Uipath Inc - Class A | Stock-Tech | 13.61% | -4.83% | EXIT | |
| 3 | DKNG | Draftkings Inc-cl A | Stock-Consumer Disc | 7.32% | -1.68% | EXIT | |
| 4 | TRDA | Entrada Therapeutics Inc | Stock-Other | 7.07% | -4.37% | — | |
| 5 | ✓ | Neuehealth Inc | Stock-Other | 3.65% | — | — | |
| 6 | RBRK | Rubrik Inc-a | Stock-Tech | 3.37% | — | NEW | |
| 7 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 2.72% | -2.05% | — | |
| 8 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 2.17% | -4.75% | — | |
| 9 | BZ | Kanzhun LTD - Adr | Stock-Other | 2.08% | — | — | |
| 10 | ✓ | Hillevax Inc | Stock-Other | 1.23% | — | — | |
| 11 | ✓ | Vacasa Inc | Stock-Other | 0.81% | — | — | |
| 12 | FRSH | Freshworks Inc-cl A | Stock-Other | 0.62% | — | — | |
| 13 | GROV | Grove Collaborative Holdings | Stock-Other | 0.53% | -0.21% | — | |
| 14 | DOCS | Doximity Inc-class A | Stock-Healthcare | 0.45% | — | — | |
| 15 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.27% | -0.13% | — | |
| 16 | AMPL | Amplitude Inc-class A | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Moneylion Inc | — | NEW | New buy |
| 2 | PATH | Uipath Inc - Class A | — | NEW | New buy |
| 3 | DKNG | Draftkings Inc-cl A | — | NEW | New buy |
| 4 | TRDA | Entrada Therapeutics Inc | — | NEW | New buy |
| 5 | ✓ | Neuehealth Inc | — | NEW | New buy |
| 6 | RBRK | Rubrik Inc-a | — | NEW | New buy |
| 7 | PHAT | Phathom Pharmaceuticals Inc | — | NEW | New buy |
| 8 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| 9 | BZ | Kanzhun LTD - Adr | — | NEW | New buy |
| 10 | ✓ | Hillevax Inc | — | NEW | New buy |
| 11 | ✓ | Vacasa Inc | — | NEW | New buy |
| 12 | FRSH | Freshworks Inc-cl A | — | NEW | New buy |
| 13 | GROV | Grove Collaborative Holdings | — | NEW | New buy |
| 14 | DOCS | Doximity Inc-class A | — | NEW | New buy |
| 15 | TNYA | Tenaya Therapeutics Inc | — | NEW | New buy |
| 16 | AMPL | Amplitude Inc-class A | — | NEW | New buy |
According to official SEC Form 13F filings, StepStone Group LP reported a total U.S. public equity portfolio value of $2.2B across 16 disclosed positions in Q1 2025.
During Q1 2025, StepStone Group LP's top holdings by market value included MONEYLION INC (54.1%)、PATH (13.6%)、DKNG (7.3%). The largest single position, MONEYLION INC, represented 54.1% of total portfolio value.
In Q1 2025, StepStone Group LP made 16 total portfolio adjustments, initiating 16 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.